Eukaryotic cells and methods for recombinantly expressing a product of interest

Number of patents in Portfolio can not be more than 2000

United States of America

PATENT NO 11203631
APP PUB NO 20170002059A1
SERIAL NO

15104580

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The disclosure pertains to novel eukaryotic cell suitable for recombinant production of a product of interest, wherein the effect of the expression product of an endogenous gene C12orf35 is impaired in said cell, thereby increasing their productivity when recombinantly expressing a polypeptide of interest. Furthermore, the present disclosure provides associated technologies wherein such host cells are used in recombinant production technologies.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • NOVARTIS AG

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Jostock, Thomas Neuenburg am Rhein, DE 22 115
Laux, Holger Basel, CH 26 32
Ritter, Anett Weil am Rhein, DE 5 3

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Jun 21, 2025
7.5 Year Payment $3600.00 $1800.00 $900.00 Jun 21, 2029
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 21, 2033
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00